CRP and inflammatory bowel disease: In the clinical trial research carried out by Ren et al. (2007), it was evidently demonstrated that in the process of utilizing TwHF for the treatment of inflammatory bowel diseases, the levels of serum C-reactive protein (CRP), TNF-α, and IL-1β were remarkably reduced.